SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018.

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14, Million by 2022, with a CAGR of from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.

*Source:

Join our expert speaker panels at the ADMET conference to ensure you do not miss out on the latest developments!

Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more.

This event is CPD ;
Event Hashtag: # SMiADMET

CHAIR: Eric Bloome, Vice President, Global Pre-Clinical Safety Senior Research Fellow, AbbVie

FEATURED SPEAKERS:
•    Pau Aceves, Associate Director, Certara Strategic Consulting
•    Peter Littlewood, Director DMPK, Vertex Pharmaceuticals
•    Filipe Lopes, Laboratory Head, DMPK, Roche
•    Andreas Reichel, VP, Head of Research Pharmacokinetics, Bayer Ag
•    Laurent Salphati, Principal Scientist, Genentech
•    Timothy Schulz-Utermoehl, Director of DMPK & Physical Sciences, Sygnature Discovery
•    Kunal Taskar, Senior DMPK Investigator, GSK
•    Robert Van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche Pharmaceuticals
•    Ian Wilson, Professor, Drug Metabolism & Molecular Toxicology, Imperial College London

KEY REASONS TO ATTEND:
The conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling software’s to the validation of humanised mice models.
Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:
•    ADME/PK Optimisation for Drug Design and Discovery 
•    Physiochemical Assessments
•    Drug Screening Technology 
•    In Vitro to Human In Vivo Translation 
•    DMPK, PBPK and PKPD Modelling
•    Pre-/Clinical Toxicity 
•    Biopharmaceuticals
•    Accurate First-in-Human Dose Predictions 
•    Transporters, Bioavailability, Formulation 
•    Metabolism Studies
•    Drug-Drug Interactions 

WHO SHOULD ATTEND

•    DMPK Professionals
•    Pharmacologists
•    Computational Scientists
•    Medicinal Chemists
•    Statisticians
•    Principle scientist
•    Drug Metabolism Experts
•    ADME Toxicologists
•    Research fellows
•    PK/PD modelling
•    Toxicologist
•    Anatomists 

EARLY BIRD-RATES
•    BOOK BY 29TH MARCH AND SAVE £400
•    BOOK BY 30TH APRIL AND SAVE £200
•    BOOK BY 31ST MAY AND SAVE £100